Abatacept Dosage
Medically reviewed by Drugs.com. Last updated on Nov 2, 2020.
Applies to the following strengths: 250 mg; 125 mg/mL; 50 mg/0.4 mL; 87.5 mg/0.7 mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Rheumatoid Arthritis
IV Dosing Regimen:
-Weight less than 60 kg: 500 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
-Weight 60 to 100 kg: 750 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
-Weight more than 100 kg: 1000 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
Subcutaneous Dosing Regimen:
-Optional IV loading dose:
---Weight less than 60 kg: 500 mg IV once
---Weight 60 to 100 kg: 750 mg IV once
---Weight more than 100 kg: 1000 mg IV once
-Subcutaneous injection: 125 mg subcutaneously once a week
Comments:
-This drug may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (DMARDs) other than Janus kinase (JAK) inhibitors or biologic disease-modifying antirheumatic drugs (bDMARDS), such as tumor necrosis factor (TNF) antagonists.
-The IV infusion should be administered over 30 minutes.
-Before the first subcutaneous dose, an optional loading dose may be administered as a single IV infusion; if an IV loading dose is used, the first subcutaneous injection should be administered within 1 day of the infusion.
-For patients switching from IV therapy to subcutaneous administration, the first subcutaneous dose should be administered instead of the next scheduled IV dose.
Use: For the treatment of patients with moderately to severely active rheumatoid arthritis
Usual Adult Dose for Psoriatic Arthritis
IV Dosing Regimen:
-Weight less than 60 kg: 500 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
-Weight 60 to 100 kg: 750 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
-Weight more than 100 kg: 1000 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
Subcutaneous Dosing Regimen: 125 mg subcutaneously once a week
Comments:
-This drug may be used with or without nonbiologic DMARDs.
-The IV infusion should be administered over 30 minutes.
-For patients switching from IV therapy to subcutaneous administration, the first subcutaneous dose should be administered instead of the next scheduled IV dose.
Use: For the treatment of patients with active psoriatic arthritis
Usual Adult Dose for Graft Versus Host Disease - Prophylaxis
10 mg/kg IV on the day before transplantation (Day -1), then 10 mg/kg IV on Days 5, 14, and 28 after transplantation
Maximum dose: 1000 mg/dose
Comments:
-Before administering this drug, recommended antiviral prophylaxis for Epstein-Barr virus (EBV) reactivation should be administered and continued for 6 months after hematopoietic stem cell transplantation (HSCT); additionally, prophylactic antivirals for CMV infection/reactivation should be considered during therapy and for 6 months after HSCT.
-The IV infusion should be administered over 60 minutes.
Use: In combination with a calcineurin inhibitor and methotrexate, for the prophylaxis of acute graft versus host disease (aGVHD) in patients undergoing HSCT from a matched or 1 allele-mismatched unrelated-donor
Usual Pediatric Dose for Juvenile Idiopathic Arthritis
IV Dosing Regimen:
6 years or older:
-Weight less than 75 kg: 10 mg/kg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
-Weight 75 to 100 kg: 750 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
-Weight more than 100 kg: 1000 mg IV initially, at 2 and 4 weeks, and every 4 weeks thereafter
Maximum dose: 1000 mg/dose
Subcutaneous Dosing Regimen:
2 years or older:
-Weight 10 to less than 25 kg: 50 mg subcutaneously once a week
-Weight 25 to less than 50 kg: 87.5 mg subcutaneously once a week
-Weight at least 50 kg: 125 mg subcutaneously once a week
Comments:
-This drug may be used as monotherapy or concomitantly with methotrexate.
-The IV infusion should be administered over 30 minutes.
-Subcutaneous administration: Patients may self-inject or the patient's caregiver may administer this drug if both the health care provider and parent/legal guardian decides it is appropriate; the ability of pediatric patients to self-inject with the autoinjector has not been tested.
Use: For the treatment of patients with moderately to severely active polyarticular juvenile idiopathic arthritis
Usual Pediatric Dose for Graft Versus Host Disease - Prophylaxis
2 to less than 6 years: 15 mg/kg IV on the day before transplantation (Day -1), then 12 mg/kg IV on Days 5, 14, and 28 after transplantation
6 years or older: 10 mg/kg IV on the day before transplantation (Day -1), then 10 mg/kg IV on Days 5, 14, and 28 after transplantation
Maximum dose: 1000 mg/dose
Comments:
-Before administering this drug, recommended antiviral prophylaxis for EBV reactivation should be administered and continued for 6 months after HSCT; additionally, prophylactic antivirals for CMV infection/reactivation should be considered during therapy and for 6 months after HSCT.
-The IV infusion should be administered over 60 minutes.
Use: In combination with a calcineurin inhibitor and methotrexate, for the prophylaxis of aGVHD in patients undergoing HSCT from a matched or 1 allele-mismatched unrelated-donor
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 2 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
IV Infusion:
-Use an infusion set and a sterile, nonpyrogenic, low-protein-binding filter (pore size of 0.2 to 1.2 microns).
-For rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriatic arthritis, administer the entire diluted solution over 30 minutes.
-For prophylaxis of aGVHD, administer the entire diluted solution over 60 minutes.
-Infusion of the diluted solution must be completed within 24 hours of reconstitution of the vials.
-Do not infuse concomitantly in the same IV line with other agents.
Subcutaneous Administration:
-The prefilled syringes and ClickJect autoinjectors are for subcutaneous use only under the guidance of a health care provider; do not use for IV infusion.
-Rotate injection sites and avoid injections into areas where the skin is tender, bruised, red, or hard.
Storage requirements:
-Refrigerate at 2C to 8C (36F to 46F); protect from light by storing in original package until time of use.
---IV infusion: May store diluted solution at room temperature or refrigerate at 2C to 8C (36F to 46F) up to 24 hours before use; discard diluted solution if not administered within 24 hours.
---Subcutaneous injection: Do not freeze.
Reconstitution/preparation techniques:
-For IV infusion: This drug must be reconstituted (using only the provided silicone-free disposable syringe) and further diluted prior to administration.
-The manufacturer product information should be consulted.
IV compatibility:
-Compatible: Sterile Water for Injection, USP; 0.9% Sodium Chloride Injection, USP
-There have been no physical or biochemical compatibility studies to evaluate coadministration of this drug with other agents.
General:
-Limitations of Use: The concomitant use of this drug with other potent immunosuppressants (e.g., bDMARDS, JAK inhibitors) is not recommended.
Monitoring:
-Infections/Infestations: For signs of infection (when transitioning from TNF antagonist therapy to this drug); for EBV reactivation; for CMV infection/reactivation (for 6 months posttransplant)
-Respiratory: For worsening respiratory status in patients with COPD
Patient advice:
-Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
-Notify health care professional immediately if symptoms of an allergic reaction occur on the day of administration or the day after administration.
-Patients treated with the IV formulation who are using glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ)-based monitoring systems for glucose: Consider using other methods for glucose monitoring (e.g., those based on glucose dehydrogenase nicotine adenine dinucleotide [GDH-NAD], glucose oxidase, or glucose hexokinase test methods) or you may get falsely elevated blood glucose readings on the day this drug is infused.
Frequently asked questions
More about abatacept
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- Reviews (59)
- En español
- Drug class: antirheumatics
Patient resources
- Drug Information
- Abatacept Intravenous (Advanced Reading)
- Abatacept Auto-Injectors
- Abatacept Infusion
- Abatacept Prefilled Syringes
- Other brands
- Orencia
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.